Cargando…

The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia

BACKGROUND: Thyroid cancer is increasing globally and is currently the most prevalent endocrine malignancy. Recent data show an increase in the incidence of thyroid cancer in the Kingdom of Saudi Arabia (KSA). Thyroid ultrasound and fine-needle aspiration cytology (FNAC) are the cornerstones in mana...

Descripción completa

Detalles Bibliográficos
Autores principales: Alyousif, Hussain, Adam, Ishag, Alamin, Naser A., Sid Ahmed, Mona A., Al Saeed, Ayat, Hassoni, Abdulmuhsen Hussein, Musa, Imad R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469765/
https://www.ncbi.nlm.nih.gov/pubmed/36111207
http://dx.doi.org/10.1177/20420188221122486
_version_ 1784788705752383488
author Alyousif, Hussain
Adam, Ishag
Alamin, Naser A.
Sid Ahmed, Mona A.
Al Saeed, Ayat
Hassoni, Abdulmuhsen Hussein
Musa, Imad R.
author_facet Alyousif, Hussain
Adam, Ishag
Alamin, Naser A.
Sid Ahmed, Mona A.
Al Saeed, Ayat
Hassoni, Abdulmuhsen Hussein
Musa, Imad R.
author_sort Alyousif, Hussain
collection PubMed
description BACKGROUND: Thyroid cancer is increasing globally and is currently the most prevalent endocrine malignancy. Recent data show an increase in the incidence of thyroid cancer in the Kingdom of Saudi Arabia (KSA). Thyroid ultrasound and fine-needle aspiration cytology (FNAC) are the cornerstones in managing thyroid nodules. We conducted this study to evaluate the prevalence and the associated predictors for thyroid nodule Bethesda III–VI in eastern KSA. METHODS: A retrospective study was conducted between January 2015 and 31 August 2021. The participants were recruited patients who received a thyroid ultrasound and ultrasound-guided thyroid FNAC, using the thyroid imaging reporting and data system (TI-RADS) and the Bethesda Classification, respectively. RESULT: Three hundred and ten patients who underwent thyroid FNAC were enrolled in the study. The median (interquartile, IQR) age was 47.0 (20.0) years, and 266 (85.8%) of them were females. The median (IQR) body mass index was 30.2 (7.6) kg/m(2). Out of these participants, 64.8% were euthyroid, 27.4% had hypothyroidism and 7.7% had hyperthyroidism. The ACR TI-RADS-3, 4 and 5 were 51.3%, 46.1% and 2.6%, respectively. The Bethesda outcome of thyroid FNAC I–VI was 5.2%, 63.9%, 15.5%, 5.8%, 3.5% and 6.1%, respectively. The risk for malignancy (Bethesda III–VI) was documented in 31.0% and atypia of undetermined significance was most prevalent (15.5%). A higher ACR TI-RADS score was associated with a higher risk of malignancy: ACR TI-RADS-3 (20.8%), ACR TI-RADS-4 (39.2%) and ACR TI-RADS-5 (87.5%). In a multivariate analysis, only the ACR TI-RADS score was significantly associated with the outcome of thyroid FNAC: ACR TI-RADS-4 [OR = 2.59 (95% CI = 1.54–4.36)] and ACR TI-RADS-5 [OR = 29.03 (95% CI = 3.44–245.07)]. CONCLUSION: There was a high prevalence of Bethesda III–VI and atypia of undetermined significance was most prevalent. A thyroid ultrasound report for TI-RADS was significantly associated with the outcome of thyroid FNAC and is a reliable tool in the absence of molecular testing for thyroid cancer.
format Online
Article
Text
id pubmed-9469765
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-94697652022-09-14 The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia Alyousif, Hussain Adam, Ishag Alamin, Naser A. Sid Ahmed, Mona A. Al Saeed, Ayat Hassoni, Abdulmuhsen Hussein Musa, Imad R. Ther Adv Endocrinol Metab Original Research BACKGROUND: Thyroid cancer is increasing globally and is currently the most prevalent endocrine malignancy. Recent data show an increase in the incidence of thyroid cancer in the Kingdom of Saudi Arabia (KSA). Thyroid ultrasound and fine-needle aspiration cytology (FNAC) are the cornerstones in managing thyroid nodules. We conducted this study to evaluate the prevalence and the associated predictors for thyroid nodule Bethesda III–VI in eastern KSA. METHODS: A retrospective study was conducted between January 2015 and 31 August 2021. The participants were recruited patients who received a thyroid ultrasound and ultrasound-guided thyroid FNAC, using the thyroid imaging reporting and data system (TI-RADS) and the Bethesda Classification, respectively. RESULT: Three hundred and ten patients who underwent thyroid FNAC were enrolled in the study. The median (interquartile, IQR) age was 47.0 (20.0) years, and 266 (85.8%) of them were females. The median (IQR) body mass index was 30.2 (7.6) kg/m(2). Out of these participants, 64.8% were euthyroid, 27.4% had hypothyroidism and 7.7% had hyperthyroidism. The ACR TI-RADS-3, 4 and 5 were 51.3%, 46.1% and 2.6%, respectively. The Bethesda outcome of thyroid FNAC I–VI was 5.2%, 63.9%, 15.5%, 5.8%, 3.5% and 6.1%, respectively. The risk for malignancy (Bethesda III–VI) was documented in 31.0% and atypia of undetermined significance was most prevalent (15.5%). A higher ACR TI-RADS score was associated with a higher risk of malignancy: ACR TI-RADS-3 (20.8%), ACR TI-RADS-4 (39.2%) and ACR TI-RADS-5 (87.5%). In a multivariate analysis, only the ACR TI-RADS score was significantly associated with the outcome of thyroid FNAC: ACR TI-RADS-4 [OR = 2.59 (95% CI = 1.54–4.36)] and ACR TI-RADS-5 [OR = 29.03 (95% CI = 3.44–245.07)]. CONCLUSION: There was a high prevalence of Bethesda III–VI and atypia of undetermined significance was most prevalent. A thyroid ultrasound report for TI-RADS was significantly associated with the outcome of thyroid FNAC and is a reliable tool in the absence of molecular testing for thyroid cancer. SAGE Publications 2022-09-12 /pmc/articles/PMC9469765/ /pubmed/36111207 http://dx.doi.org/10.1177/20420188221122486 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Alyousif, Hussain
Adam, Ishag
Alamin, Naser A.
Sid Ahmed, Mona A.
Al Saeed, Ayat
Hassoni, Abdulmuhsen Hussein
Musa, Imad R.
The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia
title The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia
title_full The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia
title_fullStr The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia
title_full_unstemmed The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia
title_short The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia
title_sort prevalence and associated predictors for bethesda iii–vi for reporting thyroid cytopathology in royal commission hospital, kingdom of saudi arabia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469765/
https://www.ncbi.nlm.nih.gov/pubmed/36111207
http://dx.doi.org/10.1177/20420188221122486
work_keys_str_mv AT alyousifhussain theprevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT adamishag theprevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT alaminnasera theprevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT sidahmedmonaa theprevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT alsaeedayat theprevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT hassoniabdulmuhsenhussein theprevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT musaimadr theprevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT alyousifhussain prevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT adamishag prevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT alaminnasera prevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT sidahmedmonaa prevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT alsaeedayat prevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT hassoniabdulmuhsenhussein prevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia
AT musaimadr prevalenceandassociatedpredictorsforbethesdaiiiviforreportingthyroidcytopathologyinroyalcommissionhospitalkingdomofsaudiarabia